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Abstract
Background: The Czech Breast Cancer Screening Programme (CBCSP) was initiated in September 2002 by
establishing a network of accredited centres. The aim of this article is to describe progress in the programme
quality over time after the inception of the organised programme.
Methods: The CBCSP is monitored using an information system consisting of three principal components: 1) the
national cancer registry, 2) a screening registry collecting data on all screening examinations, further assessments
and final diagnoses at accredited programme centres, and 3) administrative databases of healthcare payers. Key
performance indicators from the European Guidelines have been adopted for continuous monitoring.
Results: Breast cancer incidence in the Czech Republic has steadily been increasing, however with a growing
proportion of less advanced stages. The mortality rate has recently stabilised. The screening registry includes
2,083,285 records on screening episodes between 2002 and 2008. In 2007-2008, 51% of eligible women aged 45-69
were screened. In 2008, the detection rates were 6.1 and 3.7 per 1,000 women in initial and subsequent screening
respectively. Corresponding recall rates are 3.9% and 2.2%, however, it is necessary to pay attention to further
assessment performed during the screening visits. Benign to malignant open biopsy ratio was 0.1. Of invasive cases
detected in screening, 35.6% was less than 10 mm in diameter. Values of early performance indicators, as
measured by both crude and standardized estimates, are generally improving and fulfil desirable targets set by
European Guidelines.
Conclusions: Mammography screening in the Czech Republic underwent successful transformation from
opportunistic prevention to an organised programme. Values of early indicators confirm continuous improvement
in different aspects of process quality. Further stimulation of participation through invitation system is necessary to
exploit the full potential of screening mammography at the population level.
Background
Breast cancer is the most frequent malignant neoplasm
in women worldwide [1]. In the past, its incidence and
mortality in Central and Eastern European countries
were significantly lower than in Western Europe. Yet
recent changes in reproductive behaviour of women
accompanied by significant demographic changes led to
a sharp increase in breast cancer incidence in Eastern
European countries including the Czech Republic [2].
Stabilisation of mortality from breast cancer can only be
achieved through high quality screening associated with
adequate treatment of detected tumours [3]. Efficacy of
breast cancer screening by mammography in preventing
breast cancer deaths was demonstrated in randomised
controlled trials. Meta-analysis of Swedish trials showed
breast cancer mortality reduction of 29% among women
aged 50-69 years [4]. Recent meta-analyses stated mor-
tality reduction to be 15% [5], however, greater protec-
tive effect seem to be present in women between 60-69
years [6]. Screening programmes were implemented in
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sists in real populations: breast cancer mortality
decreased by 16% to 36% in populations invited to
screening and women attending at least one screening
examination could decrease their risk of death from
breast cancer by 24% to 48% [9]. On the other hand,
there are also adverse effects associated with breast can-
cer screening by mammography. Namely these include
radiation exposure, pain during mammography, anxiety
responses from screening, false-positive and false-nega-
tive results, and overdiagnosis [6]. However, there is
convincing evidence that, in certain age groups, benefits
of mammography screening outweigh its risk. This led
to recommendations for screening in United States [10]
and Europe [11].
To obtain projected benefits and minimise negative
outcomes, the programmes should be implemented with
an organised, population-based approach, with quality
assurance at all appropriate levels, and in accordance
with European Guidelines for Quality Assurance in
Breast Cancer Screening and Diagnosis [11,12]. The pol-
icy of a screening effort should be documented in a law
or an official regulation to qualify as a screening pro-
gramme [8]. IARC Handbooks of cancer prevention [13]
state six characteristics of an organised screening pro-
gramme: a policy specifying target population, screening
method and interval; a defined target population; a team
responsible for overseeing screening centres; a decision
structure and responsibility for healthcare management;
a quality assurance system utilizing relevant data; and
monitoring of cancer occurrence in the target popula-
tion. The highest level of programme organisation,
population-based screening, requires that all persons eli-
gible for screening are identified and personally invited
to attend a screening examination in each round of
screening [8].
The objective of this article is to summarize the
implementation and results of the Czech breast cancer
screening programme (CBCSP) since 2002. The evalua-
tion of CBCSP is based on a multi-source information
system including the monitoring of population cancer
burden and early performance indicators of the screen-
ing programme. Favourable values of screening perfor-
mance measures are necessary to have a significant
effect on cancer mortality in the future [14]. Therefore,
we describe the results of transformation from no-pro-
gramme opportunistic screening to a non-population
based yet highly organised programme by comparison of
measured indicators to international guideline targets
a n dp u b l i s h e dr e s u l t s .T oo u rknowledge, this is one of
the first reports from a new EU member state. Com-
pared to previous papers [15-17], this article adds new
results on long-term continuous quality improvement
after the programme initiation.
Methods
The Czech Breast Cancer Screening Programme
In the late 1990s, mammography was performed at
more than 130 facilities and screening examinations
were claimed as diagnostic. In 2002 an accreditation
programme was launched by a directive of the Czech
Ministry of Health with accreditation criteria based on
the European Guidelines [11]. The programme is admi-
nistered by the Breast Cancer Screening Committee at
t h eM i n i s t r yo fH e a l t h .T h ec e n t r e sa r eo v e r s e e nb yt h e
Expert Committee on Breast Imaging (Komise odborníků
pro mamární diagnostiku).
The CBCSP is a nationwide organized programme,
currently performed at 67 regularly monitored accre-
dited centres. The target population was defined as
women aged 45-69 years. Since 2010 there is no upper
age limit, therefore all women from 45 years of age can
attend a biennial mammography screening covered by
health insurance. Women are referred to screening
mammography by their general practitioners (GPs) or
gynaecologists on the basis of preventive check-ups, as
there is no established centralised system of direct invi-
tation yet. Women outside the target population (over
40 years of age) can undergo screening mammography
(upon direct payment of entire cost of the screening
examination) and are therefore included in aggregated
statistics.
Mammography is performed in two-views (craniocau-
dal, mediolateral oblique), independent double reading
with consensus is recommended. Both screen-film and
digital mammography systems are present. Screening
centres also act as breast assessment units, necessary
further assessment of the findings (magnification, spot
mammography, breast ultrasound, etc.) is provided dur-
ing the screening visit at the centre (one-day diagnos-
tics). Recall to the screening centre is usually employed
in case of a double reading discrepancy or for invasive
examinations, including core-cut biopsy (majority per-
formed within one week after screening). For reporting
of screening and additional imaging results, the BI-
RADS system [18] is used and for the evaluation of
breast density, typology according to Tabar was
included [19]. All of the centres provide core-cut
biopsy, special methods (MR mammography and
vacuum biopsy) are provided at a narrower network of
specialized centres.
Screening programme data are annually consolidated
from local databases of screening centres, and are subse-
quently stored in a secured central database - the Czech
Breast Cancer Screening Registry (Figure 1). Official
results containing a description of the screening process
and performance monitoring are published annually.
Feedback for screening centres is provided using annual
reporting of performance indicators.
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The Czech National Cancer Registry (CNCR) was estab-
lished in 1976. With verified 100% coverage, it contains
information on the cancer diagnosis, treatment and sur-
vival of all Czech cancer patients. A comprehensive
overview of cancer epidemiology in the Czech Republic
is available on-line at http://www.svod.cz[20].
Claims data from healthcare payers
The costs of biennial screening mammography in
women from the screening target population are reim-
bursed by public health insurance in the Czech Repub-
lic. Therefore, claims data on mammography are
available in data warehouses of healthcare payers pro-
vided via centralized exports by the Czech National
Reference Centre. These administrative records allow
for a description of the utilisation of diagnostic and
screening mammography in the Czech female popula-
tion and to monitor the prevalence of opportunistic
screening outside the organised programme.
Data analysis
Population-based data of CNCR was analysed using
standard methods [21] to detect trends in incidence and
mortality. The performance of the programme was
assessed using the standard set of performance indica-
tors introduced in European Guidelines [11]. The cover-
age of the target population by screening examination
was computed as a ratio between the number of exami-
nations in women aged 45-69 years in previous 24
months and the number of women aged 45-69 in the
target population at the end of the period.
Performance of a screening test was assessed using
breast cancer detection rates and further assessment
rates. Further assessment comprises any additional
examination performed until 6 months after screening
mammography. Screen-detected cancers comprise all
diagnosed breast cancer cases until one year after posi-
tive screening. Benign to malignant open biopsy ratio
was defined as ratio of the number of women under-
going open biopsy with benign result to the number of
women undergoing open biopsy with malignant result.
All results were stratified according to the individual
screening history of the women: initial or subsequent
screening. In order to estimate time-related trends in
further assessment rates and detection rates irrespective
of changes in age structure and in proportion of initially
screened women, standardization [22] was performed.
All analyses were performed using Stata/IC 10.1 for
Windows [23]. Providers of the utilised data consented
with their use for epidemiological research. The study
was entirely observational; therefore, no approval from
the ethical committee was required.
Results
Breast cancer burden in the Czech Republic
The incidence rate of breast cancer has been increasing
constantly since the early 1990s (65.5 cases per 100,000
women in 1990 vs. 122.7 in 2007). On the other hand,
the mortality rate was stable during the same period
(34.2 cases per 100,000 women in 1990 vs. 36.4 in 2007,
Figure 2). The peak value of breast cancer incidence can
be observed in 2003 after the introduction of an orga-
nised screening programme and again in 2007 when the
growing programme was reinforced by a pilot project
for the invitation of yet-unscreened women (see discus-
sion for description). It is clearly visible particularly in
newly introduced women aged 70-74 years (Figure 3).
The continuing rise in incidence after 2002 could be
attributed to the screening target population, i.e. women
aged 45-69 years. The incidence is stable in younger
(30-44 years) and older (75+ years) women.
The rise in incidence rate after 1990 is visible in all
postmenopausal age groups. The most recent growth is
reduced in the 70-74 age group, due to detection of
tumours at a younger age in the screening programme
(Figure 4). There is an apparent increase in the propor-
tion of stage I breast cancers which started in the early
1990s and continues after 2002 (Figure 5). This is
reflected in increase of early breast cancer rates in the
45-69 age groups. During the same period, we can wit-
ness slow decrease in advanced cancer rates (stage III
+IV, 50.5 cases per 100,000 women in 1990-1994 vs.
38.1 in 2003-2007, Figure 6).
SCREENING/IMAGING
Figure 1 Structure of a patient record in the Czech Breast
Cancer Screening Registry.
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The Czech Breast Cancer Screening Registry includes
2,083,285 records on screening episodes between 2002
and 2008. The 24-month coverage by screening mammo-
graphy steadily increased over these years (Table 1). The
coverage in the age group of 45-69 year-olds reached
51.2% in 2008. In years 2002-2004, women attended pro-
gramme screening examination for the first time (initial
screening). Since then, the proportion of subsequent
screenings has been constantly rising and reached 66% in
2008. The age of women attending screenings is also
increasing (Table 2). Recruitment is less effective in
higher age categories, the coverage decreases from 58.0%
at age 45-49 to 42.3% at age 65-69. The screening pro-
gramme was not open to elderly women (aged over 70)
free of charge before 2010. They were only invited as a
part of the pilot project in 2007-2008 and the coverage is
therefore only 14.5% of this age group (Table 3).
The crude breast cancer detection rate has been
changing a little during first years of the programme
Figure 3 Time trends in age-specific breast cancer incidence rate. Source of data: Czech National Cancer Registry.
Figure 2 Time trends of breast cancer incidence and mortality rates in the Czech Republic. Source of data: Czech National Cancer
Registry.
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rate was always higher in initially screened women
(Tables 4, 5) than in subsequently screened women
(Tables 6, 7). The detection rate increases with age in
initial (3.1-15.1 detected cases per 1,000 women
screened, Table 5) and subsequent (2.1-11.7 detected
cases per 1,000 women screened, Table 7) screenings.
Bearing the rapidly changing population structure in
mind, it is therefore more informative to study devel-
opment of age-specific rates in initial and subsequent
screenings (Figure 7) or summarize them using a stan-
dardized rate ratio (Table 1). Both show evidence for
constantly improving detection rates after the organisa-
tion of the screening programme.
The further assessment rate has been decreasing since
2003 to 12.8% in 2008 (Table 1). This indicator is also
subject to trends in age structure and the proportion of
subsequent examinations. This rate decreases with age in
initial (26.0%-10.0%, Table 5) and subsequent (16.2%-
5.7%, Table 7) screenings, being larger in initial screen-
ing. Improvement (i.e. decrease) in further assessment
rates is clear from both age-specific (Figure 8) and stan-
dardized indicators (Table 1). Trends in the recall rate
are very similar to those in the further assessment rate.
Only about 20-30% of women with positive results of
screening are being recalled back to the screening centre.
The rest of the women undergo further assessment on
the day of the screening visit. The benign to malignant
open biopsy ratio is also constantly improving (0.49 in
2002 vs. 0.10 in 2008). The ratio is similar in initially and
subsequently screened women. The youngest age groups
experience a slightly increased ratio (Tables 5, 7).
About 30% of detected breast cancer cases are
advanced (TNM stage II+, i.e. involvement of lymph
nodes and/or distant metastases) in initial screenings,
and this proportion decreases to about 20% in subse-
quent screenings (Tables 4, 6). About 90% of detected
cases are invasive in both initial and subsequent screen-
ings. Of these, 60-70% of the findings are without invol-
vement of lymph nodes (this proportion is higher in
subsequent screenings). The primary tumour in about
30-40% of invasive cases is less than 10 mm in diameter
(this proportion is higher in subsequent screenings).
Discussion
A recent study [9] reviewed current evidence on the effec-
tiveness of mammography screening in real populations.
Figure 4 Comparison of age structure of breast cancer patients
groups diagnosed in different time periods. Source of data:
Czech National Cancer Registry.
Figure 5 Time trends in distribution of clinical stages in newly diagnosed breast cancer cases in the Czech Republic.S o u r c eo fd a t a :
Czech National Cancer Registry.
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Figure 6 Time trends of breast cancer incidence rates in women aged 45-69 years, according to clinical stage at diagnosis.S o u r c eo f
data: Czech National Cancer Registry.
Table 1 Performance indicators of the Czech Breast Cancer Screening Programme, according to year of screening,
including all age groups (total)
Year (screening mammography)
2002 2003 2004 2005 2006 2007 2008
Number of women screened 10,055 212,537 265,217 317,194 340,564 469,299 468,419
Estimate of 24 m coverage by examination
(women aged 45-69)
0.6% 13.1% 27.9% 33.8% 38.1% 44.8% 51.2%
Number of women with detected breast cancer 48 1,053 1,250 1,445 1,570 2,542 2,128
Breast cancer detection rate 4.8 5.0 4.7 4.6 4.6 5.4 4.5
Standardized ratio (reference year 2008) 0.81 0.83 0.80 0.85 0.96 0.97 1.00
Number of women undergoing further assessment 1,768 46,976 57,925 56,850 53,580 63,415 60,025
Further assessment rate 17.6% 22.1% 21.8% 17.9% 15.7% 13.5% 12.8%
Standardized ratio (reference year 2008) 0.90 1.20 1.21 1.14 1.10 1.01 1.00
Number of women recalled for further assessment 557 12,095 11,725 11,931 10,429 13,977 12,955
Recall rate 5.5% 5.7% 4.4% 3.8% 3.1% 3.0% 2.8%
Women undergoing open biopsy - benign result 21 504 347 285 194 249 173
Women undergoing open biopsy - malignant result 43 867 1,021 1,259 1,347 2,149 1,794
Benign to malignant open biopsy ratio 0.49 0.58 0.34 0.23 0.14 0.12 0.10
Number of women with detected breast cancer (cases preceded by neoadjuvant
therapy excluded)
48 1,031 1,212 1,400 1,522 2,470 2,039
Advanced cases (TNM II+) 17 331 390 440 439 652 525
Advanced cases proportion 35.4% 32.1% 32.2% 31.4% 28.8% 26.4% 25.7%
Invasive cases 41 933 1,097 1,283 1,370 2,211 1,831
Invasive cases proportion 85.4% 90.5% 90.5% 91.6% 90.0% 89.5% 89.8%
Node-negative invasive cases 27 572 700 840 905 1,442 1,218
Proportion among invasive 65.9% 61.3% 63.8% 65.5% 66.1% 65.2% 66.5%
Invasive ≤ 10 mm cases 11 312 360 460 504 770 651
Proportion among invasive 26.8% 33.4% 32.8% 35.9% 36.8% 34.8% 35.6%
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tries, where mammography screening lead to an eventual
decrease in breast cancer mortality. National programmes
included Finland [24], Iceland [25], the Netherlands [26]
and the United Kingdom [27]. Regionally organised pro-
grammes included Denmark [28], Italy [29], Spain [30]
and Sweden [31,32]. All of these countries implemented
organised screening programmes in the 1980s or early
1990s. Organised screening policies in these countries
include the specification of covered age groups, screening
interval and detection methods [7]. Programmes include
quality assurance systems [33] that utilise data on screen-
ing process and also have access to cancer registry data
[34].
The CBCSP has been implemented to comprise such
organisational aspects, as recommended by the IARC work-
ing group. We made comprehensive use of three valuable
data sources (cancer registry, cancer screening registry, and
the data warehouse of healthcare payers) to continuously
monitor the success of the programme. The following dis-
cussion compares observed values of early performance
indicators with published results and European Guidelines
targets [11], which are based on the results of randomized
trials and successful screening programmes.
Epidemiology
In addition to the performance monitoring, the Czech
screening programme is supported with highly
Table 2 Time trends in basic characteristics of the population attending the screening programme
Year screened NUMBER OF WOMEN SCREENED Proportion subsequent AGE SCREENED
Initial Subsequent 5
th
percentile
25
th
percentile
Median 75
th
percentile
95
th
percentile
2002 10,055 0 0.0% 45.6 49.2 53.8 59.0 66.5
2003 212,514 23 0.0% 45.7 49.4 53.9 59.3 66.7
2004 258,635 6,582 2.5% 45.4 49.4 54.2 59.7 66.9
2005 220,897 96,297 30.4% 45.5 50.0 54.9 60.3 67.1
2006 170,717 169,847 49.9% 45.5 50.1 55.1 60.5 67.2
2007 232,509 236,790 50.5% 45.3 50.9 56.9 63.2 70.6
2008 159,273 309,146 66.0% 45.3 50.6 56.1 61.6 68.0
Table 3 Performance indicators of the Czech Breast Cancer Screening Programme, according to age group, women
screened in 2008 (total)
Age group Total
45-69
Total
50-69
45-49 50-54 55-59 60-64 65-69 70-74
Number of women screened 95,883 106,232 105,578 90,394 55,427 4,848 453,514 357,631
Estimate of 24 m coverage by examination 58.0% 55.0% 51.6% 47.5% 42.3% 14.5% 51.2% 49.6%
Number of women with detected breast cancer 254 374 416 577 409 67 2,030 1,776
Breast cancer detection rate 2.6 3.5 3.9 6.4 7.4 13.8 4.5 5.0
Number of women undergoing further assessment 20,881 14,923 10,318 7,174 3,959 409 57,255 36,374
Further assessment rate 21.8% 14.0% 9.8% 7.9% 7.1% 8.4% 12.6% 10.2%
Number of women recalled for further assessment 3,652 2,913 2,421 2,149 1,291 162 12,426 8,774
Recall rate 3.8% 2.7% 2.3% 2.4% 2.3% 3.3% 2.7% 2.5%
Women undergoing open biopsy - benign result 50 40 27 31 21 1 169 119
Women undergoing open biopsy - malignant result 211 315 368 481 334 58 1,709 1,498
Benign to malignant open biopsy ratio 0.24 0.13 0.07 0.06 0.06 0.02 0.10 0.08
Number of women with detected breast cancer (cases preceded by
neoadjuvant therapy excluded)
239 352 401 555 399 65 1,946 1,707
Advanced cases (TNM II+) 63 98 104 131 95 27 491 428
Advanced cases proportion 26.4% 27.8% 25.9% 23.6% 23.8% 41.5% 25.2% 25.1%
Invasive cases 216 315 343 508 360 63 1,742 1,526
Invasive cases proportion 90.4% 89.5% 85.5% 91.5% 90.2% 96.9% 89.5% 89.4%
Node-negative invasive cases 131 196 238 342 255 38 1,162 1,031
Proportion among invasive 60.6% 62.2% 69.4% 67.3% 70.8% 60.3% 66.7% 67.6%
Invasive ≤ 10 mm cases 70 110 119 179 146 19 624 554
Proportion among invasive 32.4% 34.9% 34.7% 35.2% 40.6% 30.2% 35.8% 36.3%
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Page 7 of 13Table 4 Performance indicators of the Czech Breast Cancer Screening Programme, according to year of screening,
including all age groups (initial screening)
Year (screening mammography)
2002 2003 2004 2005 2006 2007 2008
Number of women screened 10,055 212,514 258,635 220,897 170,717 232,509 159,273
Number of women with detected breast cancer 48 1,053 1,220 1,153 935 1,662 974
Breast cancer detection rate 4.8 5.0 4.7 5.2 5.5 7.1 6.1
Number of women undergoing further assessment 1,768 46,973 56,961 44,919 33,135 39,921 30,239
Further assessment rate 17.6% 22.1% 22.0% 20.3% 19.4% 17.2% 19.0%
Number of women recalled for further assessment 557 12,095 11,535 9,735 6,496 8,888 6,246
Recall rate 5.5% 5.7% 4.5% 4.4% 3.8% 3.8% 3.9%
Women undergoing open biopsy - benign result 21 504 343 226 135 166 90
Women undergoing open biopsy - malignant result 43 867 992 994 787 1,382 784
Benign to malignant open biopsy ratio 0.49 0.58 0.35 0.23 0.17 0.12 0.11
Number of women with detected breast cancer (cases preceded by neoadjuvant
therapy excluded)
48 1,031 1,182 1,116 905 1,610 924
Advanced cases (TNM II+) 17 331 384 367 284 465 277
Advanced cases proportion 35.4% 32.1% 32.5% 32.9% 31.4% 28.9% 30.0%
Invasive cases 41 933 1,072 1,023 823 1,459 850
Invasive cases proportion 85.4% 90.5% 90.7% 91.7% 90.9% 90.6% 92.0%
Node-negative invasive cases 27 572 682 644 525 909 535
Proportion among invasive 65.9% 61.3% 63.6% 63.0% 63.8% 62.3% 62.9%
Invasive ≤ 10 mm cases 11 312 350 348 288 441 275
Proportion among invasive 26.8% 33.4% 32.6% 34.0% 35.0% 30.2% 32.4%
Table 5 Performance indicators of the Czech Breast Cancer Screening Programme, according to age group, women
screened in 2008 (initial screening)
Age group Total
45-69
Total
50-69
45-49 50-54 55-59 60-64 65-69 70-74
Number of women screened 54,495 26,214 26,694 24,452 16,067 3,047 147,922 93,427
Number of women with detected breast cancer 169 126 150 245 211 46 901 732
Breast cancer detection rate 3.1 4.8 5.6 10.0 13.1 15.1 6.1 7.8
Number of women undergoing further assessment 14,188 5,097 3,749 2,998 1,808 306 27,840 13,652
Further assessment rate 26.0% 19.4% 14.0% 12.3% 11.3% 10.0% 18.8% 14.6%
Number of women recalled for further assessment 2,430 1,007 845 901 626 124 5,809 3,379
Recall rate 4.5% 3.8% 3.2% 3.7% 3.9% 4.1% 3.9% 3.6%
Women undergoing open biopsy - benign result 35 18 8 14 11 1 86 51
Women undergoing open biopsy - malignant result 135 101 132 194 161 38 723 588
Benign to malignant open biopsy ratio 0.26 0.18 0.06 0.07 0.07 0.03 0.12 0.09
Number of women with detected breast cancer
(cases preceded by neoadjuvant therapy excluded)
159 115 144 233 205 44 856 697
Advanced cases (TNM II+) 47 34 45 72 55 19 253 206
Advanced cases proportion 29.6% 29.6% 31.3% 30.9% 26.8% 43.2% 29.6% 29.6%
Invasive cases 146 106 129 216 189 42 786 640
Invasive cases proportion 91.8% 92.2% 89.6% 92.7% 92.2% 95.5% 91.8% 91.8%
Node-negative invasive cases 83 68 85 136 124 24 496 413
Proportion among invasive 56.8% 64.2% 65.9% 63.0% 65.6% 57.1% 63.1% 64.5%
Invasive ≤ 10 mm cases 47 32 42 64 73 10 258 211
Proportion among invasive 32.2% 30.2% 32.6% 29.6% 38.6% 23.8% 32.8% 33.0%
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Page 8 of 13Table 6 Performance indicators of the Czech Breast Cancer Screening Programme, according to year of screening,
including all age groups (subsequent screening)
Year (screening mammography)
2004 2005 2006 2007 2008
Number of women screened 6,582 96,297 169,847 236,790 309,146
Number of women with detected breast cancer 30 292 635 880 1,154
Breast cancer detection rate 4.6 3.0 3.7 3.7 3.7
Number of women undergoing further assessment 964 11,931 20,445 23,494 29,786
Further assessment rate 14.6% 12.4% 12.0% 9.9% 9.6%
Number of women recalled for further assessment 190 2,196 3,933 5,089 6,709
Recall rate 2.9% 2.3% 2.3% 2.1% 2.2%
Women undergoing open biopsy - benign result 4 59 59 83 83
Women undergoing open biopsy - malignant result 29 265 560 767 1,010
Benign to malignant open biopsy ratio 0.14 0.22 0.11 0.11 0.08
Number of women with detected breast cancer (cases preceded by neoadjuvant therapy excluded) 30 284 617 860 1,115
Advanced cases (TNM II+) 6 73 155 187 248
Advanced cases proportion 20.0% 25.7% 25.1% 21.7% 22.2%
Invasive cases 25 260 547 752 981
Invasive cases proportion 83.3% 91.5% 88.7% 87.4% 88.0%
Node-negative invasive cases 18 196 380 533 683
Proportion among invasive 72.0% 75.4% 69.5% 70.9% 69.6%
Invasive ≤ 10 mm cases 10 112 216 329 376
Proportion among invasive 40.0% 43.1% 39.5% 43.8% 38.3%
Table 7 Performance indicators of the Czech Breast Cancer Screening Programme, according to age group, women
screened in 2008 (subsequent screening)
Age group Total
45-69
Total
50-69
45-49 50-54 55-59 60-64 65-69 70-74
Number of women screened 41,388 80,018 78,884 65,942 39,360 1,801 305,592 264,204
Number of women with detected breast cancer 85 248 266 332 198 21 1,129 1,044
Breast cancer detection rate 2.1 3.1 3.4 5.0 5.0 11.7 3.7 4.0
Number of women undergoing further assessment 6,693 9,826 6,569 4,176 2,151 103 29,415 22,722
Further assessment rate 16.2% 12.3% 8.3% 6.3% 5.5% 5.7% 9.6% 8.6%
Number of women recalled for further assessment 1,222 1,906 1,576 1,248 665 38 6,617 5,395
Recall rate 3.0% 2.4% 2.0% 1.9% 1.7% 2.1% 2.2% 2.0%
Women undergoing open biopsy - benign result 15 22 19 17 10 0 83 68
Women undergoing open biopsy - malignant result 76 214 236 287 173 20 986 910
Benign to malignant open biopsy ratio 0.20 0.10 0.08 0.06 0.06 0.00 0.08 0.07
Number of women with detected breast cancer
(cases preceded by neoadjuvant therapy excluded)
80 237 257 322 194 21 1,090 1,010
Advanced cases (TNM II+) 16 64 59 59 40 8 238 222
Advanced cases proportion 20.0% 27.0% 23.0% 18.3% 20.6% 38.1% 21.8% 22.0%
Invasive cases 70 209 214 292 171 21 956 886
Invasive cases proportion 87.5% 88.2% 83.3% 90.7% 88.1% 100.0% 87.7% 87.7%
Node-negative invasive cases 48 128 153 206 131 14 666 618
Proportion among invasive 68.6% 61.2% 71.5% 70.5% 76.6% 66.7% 69.7% 69.8%
Invasive ≤ 10 mm cases 23 78 77 115 73 9 366 343
Proportion among invasive 32.9% 37.3% 36.0% 39.4% 42.7% 42.9% 38.3% 38.7%
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whole population since 1977. Breast cancer incidence
has been rising steadily since 1980s. However, further
increase in mortality has been arrested after 1995, simi-
larly to other member states of the European Union [3].
The stabilized breast cancer mortality in the Czech
Republic can be at least partially attributed to the
improving stage distribution of newly diagnosed breast
cancer cases and mild decrease in rate of advanced
tumours. Nevertheless, part of the increase in early
tumours rate is attributable to overdiagnosis - screen-
detected cancers that would not have surfaced clinically
during the woman’s lifetime [35]. Estimate of the pro-
portion of overdiagnosed tumours ranges to over 50%
[36]; however, most of the estimates vary from 1% to
10% [6]. Very gradual expansion of opportunistic and
organised screening does not yet allow us to estimate
extent of overdiagnosis precisely using epidemiology
data; therefore, we have concentrated on assessment of
early performance indicators. As their values of detec-
tion rates and DCIS proportion comply with European
Guidelines targets quite well (see bellow), we do not
assume overdiagnosis to markedly excess values seen in
clinical and epidemiological studies abroad.
Coverage
The current Czech system of recruitment through GPs
or gynaecologists, reinforced by media campaigns and
recall for subsequent screenings by screening centres
was able to achieve a modest coverage of 50%. The
advantage of this setup is the primary care physician’s
full knowledge of the patient’s medical history and pre-
ferences, which enables the proper tailoring of an indivi-
dual preventive strategy. Nevertheless, participation
rates in successful population-based programmes
approach the European Guidelines target of 70% (e.g.
Spain [37], United Kingdom [38], Denmark [39]), or
even exceed them (Finland [40]). However, the invita-
tion may also fail to achieve the stated target (e.g.
decentralized invitation in Hungary [16], invitation with-
out appointment in Luxembourg [41]) - it is therefore
necessary to properly plan, implement and monitor the
invitation process.
Pilot project
That is why in 2007-2008 a pilot project of centralised
invitation of non-attending women was undertaken. The
project was carried out by the General Health Insurance
Company (GHIC). GHIC is the principal provider of
health insurance in the Czech Republic, with more than
6.5 million clients (about two thirds of the Czech popu-
lation). A total number of 598,637 women aged between
45 and 74 years were invited for screening mammogra-
phy (the invited women had not undergone mammogra-
phy examination during the last three years). The
women invited to the pilot project were screened
between July 2007 and February 2008. Overall, 107,264
women (i.e., 18% of those invited) were screened at 60
mammography screening facilities. As regards the target
population (45-69 years), 491,294 women were invited
and 16.4% of them were screened. Participation rate was
higher in older women (24.7%).
Despite the relatively low participation rate in the pro-
ject itself, the project helped to substantially increase
coverage in the target population (from 38.1% in 2006
to 51.2% in 2008), especially in elder women. Further-
more, the pilot project also invited women aged 70-74
and the outcomes of the screening in this group are visi-
ble in the epidemiology data. The pilot project con-
firmed a high sensitivity and specificity of
mammography in these elderly groups and led to the
Figure 7 Breast cancer detection rate: age-specific comparison
of time periods.
Figure 8 Further assessment rate: age-specific comparison of
time periods.
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Page 10 of 13extension of the age groups targeted by the Czech
screening programme in 2010.
Opportunistic activities
Screening activities occurring outside the programme or
before its inception are referred to as ‘opportunistic’
screening. Opportunistic screening may fail to exploit
the full potential of mammography to prevent deaths
from breast cancer [42]. A possible explanation includes
less sensitivity [43] and subsequently less-favourable
prognostic features of detected tumours [44]. It is less
cost-effective, mainly due to higher cost of diagnostic
mammography and overuse of additional imaging in an
unorganized setting [45,46]. Dissemination of organised
mammography screening can increase programme cov-
erage [17] and also attract more disadvantaged women
[47]. It is therefore advisable to promote the highest
level of organisation possible, with close monitoring of
performance indicators [14].
Intensified nationwide organisation led to an increase
in opportunistic mammography activities in Hungary
[17]. Yet Jensen [48] concluded that, in Denmark,
women not attending an organised programme did not
seek the service elsewhere and proportion of women
screened outside the programme was 1-4% in Danish
counties. According to monitoring performed by the
Czech healthcare payers, the non-programme screening
was quite prevalent in the Czech Republic before the
onset of the organized programme. In 2002, the propor-
tion of women undergoing non-programme examination
was over 15% and approached 25% in some regions. In
the following years, the overall proportion has been
decreasing below 10%; however, it still remains high in
some regions.
Sensitivity of the programme
Important early indirect measures of test and pro-
gramme sensitivity include detection rate, stage distribu-
tion of detected cancers and incidence of interval
cancers [11,14].
The presence of opportunistic screening and gradual
recruitment into organised screening make it difficult to
estimate incidence rates expected in the target popula-
tion in the absence of screening (background incidence),
which is necessary to interpret detection and interval
cancer rates. Anyway, a rough estimate could be
acquired by averaging pre-programme breast cancer
rates. The resulting ratio of detection rate to back-
ground incidence rate in initial screening for women
aged 50-69 years is 4.1, which is in accordance with
European Guidelines and similar to values observed in
European pilot projects [49].
Easily observable measures of stage distribution are
defined in European Guidelines. The proportion of
advanced tumours and the proportion of small invasive
tumours achieved the desirable levels given by European
Guidelines. On the other hand, the proportion of node-
negative invasive tumours keeps staying below accepta-
ble level. However, modern pathology techniques may
lead to increased detection of node metastases of lesser
clinical significance [50,51] and targets might need to be
restated in light of the new epidemiological data.
Precise estimation of interval cancer rates has not yet
been possible in the Czech screening, due to the non-
existing direct individual link between the cancer regis-
try and the cancer screening registry. Prediction of the
rate is possible, e.g. using the Markov model [52], how-
ever, we don’t consider this approach for continuous
monitoring of performance indicators.
Safety and efficiency of the programme
A specific feature of the CBCSP is one-day diagnostics.
Providing final results of a screening examination to the
women during the screening visit definitely prevents a
great amount of adverse psychological consequences
drawn by the screening programme [53] and provides a
sufficient level comfort. Yet, it might be quite demand-
ing for the staff of the screening centres and might
increase the further assessment rate, because the women
are readily available at the screening centre during the
mammogram assessment. Indeed, despite the continu-
ous decrease in time, further assessment remains 2-3
times higher than in Western and Northern European
countries [54]. Recall rates are nevertheless similar, as
only some of women with further assessment are actu-
ally recalled back to the screening centre.
The high positive predictive value of further assess-
ment is provided by the successful adoption of preo-
perative diagnostics with core biopsy. This part of the
screening process is reflected by a benign to malignant
open biopsy ratio, one of the key indicators in the Eur-
opean Guidelines. Results in the CBCSP achieved the
desirable target in the Guidelines and became fully com-
parable to long operating population-based screening
programmes, e.g. in Finland and Italy [40,55].
Conclusions
The transformation from opportunistic prevention to an
organised programme facilitated continuous improve-
ment in the quality of offered mammography screening
examinations. Most performance indicators reach targets
set by European Guidelines and observed in successful
population-based programmes around Europe. This pro-
mises effectiveness, safety and efficiency similar to ran-
domized clinical trials, which justifies the enormous
investment into programme initiation and operation.
The important task now is to implement addressed invi-
tations to the screenings and to institute a system for
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Page 11 of 13monitoring the impact of cancer screening on popula-
tion epidemiology, including examination of the possible
risk of overdiagnosis.
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